18 results about "Bacillus fragilis" patented technology

The application provides application of Bacteroides fragilis in improving and / or treating diarrhea. It is proved by different mouse diarrhea model tests that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No. 10685 or inactivated bacteria thereof have the effects of improving and treating diarrhea. The inactivated bacteria powder of the Bacteroides fragilis has better effects on improving infectious diarrhea or non-infectious diarrhea under different concentration formulations, has no side effects on the body, has a good edible and application prospect, and provides a good product suitable for human consumption for health care and improvement of diarrhea.

The present invention discloses an intestinal microbiota Bacteroides fragilis toxin-neutralizing nanobody and its application. By deeply studying the enterotoxigenic Bacteroides fragilis and the toxin BFT secreted by it in the bodies of patients with colorectal cancer and breast cancer, nanobodies against BFT are expressed by phage display technology; nanobodies with high binding affinity to the antigen are screened out through biopanning technology; a nanobody with the ability to neutralize the toxicity of BFT, also known as Nb2.43, is obtained. The present invention expresses and optimizes to obtain a BFT nanobody protein with high affinity, stability and uniformity, opening up a new field for the treatment of colorectal cancer and breast cancer with nanobodies targeting BFT, and having good research value and application prospects.

A microorganism containing Bacteroides fragilis genes is used as an active ingredient in the preparation of pharmaceuticals, medical devices, or food for treating optic nerve damage. This delivers Bacteroides fragilis (or its functional components) into the gastrointestinal tract, which helps maintain the number of retinal ganglion cells and the thickness of the retinal nerve fiber layer, inhibits the activation of retinal microglia, inhibits the activation of retinal inflammatory pathways and the expression of inflammatory mediators, thereby protecting visual function.

The microorganism contains the bacteroides fragilis gene, and the bacteroides fragilis gene is used as an active ingredient to be applied to preparation of medicine or food for treating optic nerve damage, the bacteroides fragilis (or functional components thereof) is delivered to gastrointestinal tracts, the number of retinal ganglion cells and the thickness of a retinal nerve fiber layer can be maintained, activation of retinal microglia cells is inhibited, and optic nerve damage is inhibited. Retina inflammation pathway activation and inflammatory mediator expression are inhibited, so that the visual function is protected.

This invention discloses novel specific molecular targets for *Bacteroides fragilis* and its BFS17, along with a rapid detection method. The molecular target nucleotide sequence of *Bacteroides fragilis* is shown in SEQ ID NO.1, and the molecular target nucleotide sequence of *Bacteroides fragilis* BFS17 is shown in SEQ ID NO.2. This invention uses a pan-genomic approach to obtain the specific core genes of *Bacteroides fragilis* and the probiotic strain *Bacteroides fragilis* BFS17, and designs characteristic primers that can sensitively detect *Bacteroides fragilis* and the probiotic strain *Bacteroides fragilis* BFS17. Furthermore, this method can rapidly and easily distinguish *Bacteroides fragilis*, the probiotic strain *Bacteroides fragilis* BFS17, and other microbial strains. This invention has the advantages of being simple and rapid to operate, highly specific, quantifiable, and inexpensive.

The invention belongs to the technical field of microbial genetic engineering and protein delivery, and particularly relates to an engineered bacterial secretion system for efficiently delivering protein and application of the engineered bacterial secretion system. Specifically, on the basis of analyzing a delivery mechanism of bacteroides fragilis GS086 type double-effect protein T6SS, engineering modification is performed on a toxic structural domain of the effect protein, and a bacterial secretion system capable of efficiently and simultaneously delivering a plurality of proteins is constructed. According to the system, a modified strain is a natural human intestinal symbiotic bacterium, the problems of high immunogenicity, poor stability and the like are effectively avoided, and protein can be delivered in situ in the intestinal tract to realize precise regulation and control of an intestinal flora structure and secretion of specific target protein, so that the system has a good practical application value.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.

The invention relates to the technical field of biology, in particular to bacteroides fragilis FMBL Ba24006 DMX for metabolism of pectic polysaccharides and application, the bacteroides fragilis FMBL Ba24006 DMX is preserved in China Center for Type Culture Collection on January 20, 2026, the preservation number is CCTCC M 2026175, the bacteroides fragilis FMBL Ba24006 DMX has good pectin metabolism capacity, pectin can be effectively used as a carbon source to achieve rapid proliferation, and meanwhile, the bacteroides fragilis FMBL Ba24006 DMX can be used for metabolism of pectic polysaccharides. The bacterial strain has a good antibacterial effect on hemorrhagic Escherichia coli; the compound is sensitive and moderately sensitive to cefoxitin and rifampicin. The strain can produce a large amount of short-chain fatty acid when being used for fermenting pectin, and fermentation liquor taking the pectin as a carbon source has relatively strong scavenging capacity on DPPH and ABTS free radicals; a relatively good inhibition effect is achieved on the activity of alpha-amylase; the method can be used for preparing antioxidant products, fermented foods, health-care products, food additives and feeds, and has a wide application prospect.

The invention belongs to the technical field of disease prognosis and molecular biology, and relates to a flora marker for colorectal cancer liver metastasis diagnosis and liver metastasis risk assessment and application of the flora marker. The marker comprises the following three strains: bifidobacterium bifidum, bacteroides fragilis and bacteroides heparinidolyticus. The method comprises the following steps: acquiring information of microorganisms in excrement of a patient through a high-resolution metagenomics detection technology; a random forest algorithm is utilized to construct a colorectal cancer liver metastasis classification model based on the flora markers, the model can distinguish people without colorectal cancer metastasis and people with liver metastasis and accurately predict high-risk patients with colorectal cancer liver metastasis, and the effect of the model is superior to that of a clinical conventional tumor serum marker. The kit has the advantages of noninvasive detection and high accuracy, and can provide a reliable tool for liver metastasis diagnosis and individualized prognosis management of colorectal cancer patients.

Provided in the present application are a real-time quantitative detection method for next-generation probiotics on the basis of flow cytometry and the use thereof. The next-generation probiotics comprise Akkermansia muciniphila and / or Bacteroides fragilis. In the present application, flow cytometry is used in the detection of next-generation probiotics to provide quantitative data of viable and non-viable cells in real time, thereby rapidly completing the high-throughput detection of viable cells in a sample while reducing the risk of contamination during the detection process. Moreover, the detection method can also detect next-generation probiotics that are unculturable due to insufficient metabolic activity, offering rapid detection speed and high accuracy.

The invention provides difunctional tremella polysaccharide as well as a preparation method and application thereof, the tremella polysaccharide is prepared by adopting a water extraction method, and the steps of crushing and sieving, hot water extraction, centrifugal separation, vacuum concentration, alcohol precipitation, Sevag deproteinization, dialysis, acidolysis, dialysis and freeze drying are performed. The trifluoroacetic acid degradation method has the characteristics of rapidness, high efficiency, simplicity and easiness in operation, the neutral sugar content of the prepared tremella polysaccharide is greater than or equal to 74%, the uronic acid content is greater than or equal to 21%, and the purity is greater than or equal to 96%. The difunctional tremella polysaccharide can significantly promote proliferation and secretion of nitric oxide NO of RAW264.7 macrophages, and significantly promote proliferation of bacteroides multiforme, bacteroides simplex, bacteroides ovale, bacteroides fragilis, bifidobacterium longum subsp. Longum, bifidobacterium breve, bacteroides bacteria, bifidobacterium bacteria and mixed bacteria. The compound has the advantages of being high in purity, activating macrophages and promoting probiotic proliferation, and can be applied to food and health care products.

The invention provides bacteroides fragilis capable of relieving enteritis and application of the bacteroides fragilis, and belongs to the technical field of microorganisms. The Bacteroides fragilis is Bacteroides fragilis NJ, the preservation number of the Bacteroides fragilis NJ in the China General Microbiological Culture Collection Center is CGMCC No.46606, and the Bacteroides fragilis NJ has the effects of inhibiting colonization of pathogenic enterobacteria, relieving host colon tissue lesions and intestinal inflammation, effectively reducing the level of inflammatory cytokines such as TNF-alpha and IL-17 in serum, and improving the immunogenicity of the serum. The abundance of enterotoxin-producing bacteroides fragilis in intestinal tracts is reduced; and a new way and method can be provided for prevention and treatment of intestinal inflammation.

The present application relates to a strain of Bacteroides fragilis and its application, the strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 14, 2026, and the preservation number is: CGMCC No. 38257.The strain can regulate STING-dependent training immunity, effectively resist Salmonella typhimurium and H9N2 avian influenza virus infection, maintain the integrity of the intestinal barrier of the host, and reduce inflammatory damage.The Bacteroides fragilis of the present application has good biological safety, and the strain can be used as a training immunity inducer, and the strain is expected to be a candidate probiotic or vaccine adjuvant for preventing / treating bacterial and viral infections, suitable for human health and poultry farming, and provides a new solution to resist antibiotic resistance.

The invention discloses a recombinase combination suitable for bacteroides, application and a homologous recombination method, and belongs to the technical field of microbial genetic engineering. The invention discloses a method for constructing and screening a combination of a single-chain annealing protein and a single-chain binding protein for the first time. A single-chain annealing protein and a single-chain binding protein are jointly constructed in an escherichia coli-bacteroides fragilis shuttle expression vector, and co-expression of the escherichia coli-bacteroides fragilis shuttle expression vector in bacteroides fragilis is achieved, so that the homologous recombination capacity of bacteroides fragilis is remarkably improved. According to the method disclosed by the invention, the homologous recombination efficiency of genome editing of bacteroides fragilis is greatly improved, the absolute editing efficiency of the genome is improved to 0.052% from the original level which is almost undetectable, and the research and application progress of genome engineering of the strain is remarkably promoted.

The invention relates to the technical field of functional microorganism application, and particularly provides a synbiotics preparation with a function of relieving type 2 diabetes and application of the synbiotics preparation. According to the synbiotics preparation provided by the invention, through the synergistic effect of the three probiotics of bacteroides fragilis, bifidobacterium animalis subsp. Lactis and phytobacterium plantarum and the prebiotics, the blood lipid metabolism disorder of mice with the type 2 diabetes mellitus can be effectively regulated, the level of TNF-alpha and IL-6 inflammatory factors in serum of the mice is remarkably reduced, and the synbiotics preparation has the effect of relieving the type 2 diabetes mellitus.

The application discloses application of Bacteroides fragilis in preparation of products for preventing and / or treating celiac disease, and a composition containing Bacteroides fragilis for treating and / or preventing celiac disease. The application proves through a large number of experiments that Bacteroides fragilis, especially Bacteroides fragilis ZY-312 with a preservation number of CGMCC No. 10685, can increase the expression of tight junction related proteins, improve intestinal barrier permeability, down-regulate TTG-IgA antibodies and pro-inflammatory factors IFN gamma and IL-15, reduce inflammation, and effectively prevent and treat celiac disease.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

The present application belongs to the field of molecular biology detection, and particularly relates to detection of wound infection related pathogens, more particularly to detection of at least four types of pathogens in Streptococcus, Bacteroides fragilis, Bacteroides, Conidiobolus corruptus and Red hair moss fungus, so as to determine the infection source as early as possible and provide corresponding prevention and control measures in a targeted and timely manner. The composition of the present application has higher detection sensitivity of 500 copies / mL, good specificity, more accurate detection, can provide sufficient rapid detection and basis for excluding infection of different pathogens, shortens the judgment time of wound infection causes, and accelerates the implementation of response measures.